Strong Financial Performance at United Imaging Healthcare
United Imaging Healthcare, a leader in advanced medical imaging and radiotherapy equipment, has recently shared its financial results for the initial three quarters of 2025. The report reveals a strong performance characterized by impressive revenue and net profit increases. The revenue surged to CNY 8.86 billion, marking a year-over-year growth of 27.39%, while net profit attributable to ordinary shareholders reached CNY 1.05 billion, a stunning increase of 126.94%.
Impressive Growth in Q3 2025
During Q3 2025, the company reported a revenue of CNY 2.84 billion, demonstrating a remarkable 75.41% increase compared to the same period last year. The net profit gained in this quarter reached CNY 0.09 billion after adjusting for non-recurring profits. These figures underscore the remarkable upward trajectory of United Imaging Healthcare's financial health.
Driving Growth Through Innovation
The company's growth has been significantly influenced by the introduction of innovative high-end medical products, which have gained strong recognition in the market. In the first three quarters of 2025, the overseas revenue alone reached CNY 1.9 billion, reflecting a year-on-year increase of 41.97% and constituting 22.5% of the total revenue.
Investment in Research and Development
Research and development (R&D) continue to be central to United Imaging's growth strategy. In the first three quarters of the year, R&D investment amounted to CNY 1.86 billion, highlighting a 13.48% increase from the previous year. This commitment to innovation has led to the introduction of several new products, including the uMR Ultra, known for its advanced features, and others like uMI Panvivo and uAngio AVIVA.
Regulatory Approvals Boost Product Portfolio
On September 29, 2025, it was announced that China’s National Medical Products Administration (NMPA) granted approval for the new-generation 3T MRI, uMR Ultra. With prior certifications from the FDA and obtaining the CE mark, this product is paving the way for global clinical access, significantly broadening United Imaging's market presence.
Global Reach and Future Outlook
As of the date of this report, United Imaging Healthcare has successfully introduced over 140 innovative products in various markets. Out of these, a notable 56 have received approval from the U.S. FDA through the 510(k) process, while 64 products are CE certified. The company currently operates in over 90 regions worldwide, showcasing its substantial international footprint.
Commitment to Healthcare Advancements
Looking forward, United Imaging Healthcare remains dedicated to driving innovation and meeting global healthcare demands. The company plans to continuously enhance its international presence, serve diverse healthcare systems globally, and contribute to the long-term advancement of health in communities worldwide.
Frequently Asked Questions
What were the revenue results for United Imaging Healthcare in Q3 2025?
The company reported a remarkable revenue of CNY 2.84 billion in Q3 2025, which is a 75.41% increase compared to the same period last year.
How much did the R&D investment grow?
In the first three quarters of 2025, the R&D investment reached CNY 1.86 billion, reflecting a 13.48% increase from the previous year.
What new products were launched by United Imaging?
Notable new products include the uMR Ultra, uMI Panvivo, and uAngio AVIVA, which have contributed to the company's revenue growth.
How significant is the overseas revenue to the company?
Overseas revenue accounted for 22.5% of total revenue, which translates to CNY 1.9 billion, marking a significant year-over-year growth of 41.97%.
What are United Imaging's future plans?
The company plans to focus on innovation-driven development, expanding its international market presence and enhancing the healthcare systems it serves worldwide.
